AU2001236782A1 - 34p3d7: a tissue specific protein highly expressed in prostate cancer - Google Patents
34p3d7: a tissue specific protein highly expressed in prostate cancerInfo
- Publication number
- AU2001236782A1 AU2001236782A1 AU2001236782A AU3678201A AU2001236782A1 AU 2001236782 A1 AU2001236782 A1 AU 2001236782A1 AU 2001236782 A AU2001236782 A AU 2001236782A AU 3678201 A AU3678201 A AU 3678201A AU 2001236782 A1 AU2001236782 A1 AU 2001236782A1
- Authority
- AU
- Australia
- Prior art keywords
- prostate cancer
- specific protein
- highly expressed
- tissue specific
- protein highly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G01N33/57585—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G01N33/57555—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18102000P | 2000-02-08 | 2000-02-08 | |
| US60181020 | 2000-02-08 | ||
| PCT/US2001/004094 WO2001059110A2 (en) | 2000-02-08 | 2001-02-08 | 34p3d7: a tissue specific protein highly expressed in prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001236782A1 true AU2001236782A1 (en) | 2001-08-20 |
Family
ID=22662558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001236782A Abandoned AU2001236782A1 (en) | 2000-02-08 | 2001-02-08 | 34p3d7: a tissue specific protein highly expressed in prostate cancer |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20020150972A1 (en) |
| AU (1) | AU2001236782A1 (en) |
| WO (1) | WO2001059110A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020127578A1 (en) * | 2000-11-27 | 2002-09-12 | Susana Salceda | Compositions and methods relating to prostate specific genes and proteins |
| WO2003085121A2 (en) * | 2002-04-01 | 2003-10-16 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002520054A (en) * | 1998-07-14 | 2002-07-09 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of prostate cancer |
| AU5047800A (en) * | 1999-05-28 | 2000-12-18 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
-
2001
- 2001-02-08 AU AU2001236782A patent/AU2001236782A1/en not_active Abandoned
- 2001-02-08 WO PCT/US2001/004094 patent/WO2001059110A2/en not_active Ceased
- 2001-02-08 US US09/779,308 patent/US20020150972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020150972A1 (en) | 2002-10-17 |
| WO2001059110A3 (en) | 2002-02-21 |
| WO2001059110A2 (en) | 2001-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002258990A1 (en) | Improvements in ablation therapy | |
| AU2001253140A1 (en) | Tumor markers in ovarian cancer | |
| AU2002211835A1 (en) | Oncology tissue microarrays | |
| WO2001016852A8 (en) | User interface for semi-fungible trading | |
| AU2002230860A1 (en) | Skin desinfectant applicator | |
| AU2003235470A1 (en) | Predictive markers in cancer therapy | |
| AU2001251348A1 (en) | Apparatus for sensing human prostate tumor | |
| AU2001249626A1 (en) | Cathepsin inhibitors in cancer treatment | |
| AU2001259702A1 (en) | Tissue regrafting | |
| IL206604A0 (en) | Transmembrane protein expressed in prostate cancer | |
| AU2001290860A1 (en) | Spas-1 cancer antigen | |
| AU2001285232A1 (en) | Alpha-difluoromethylornithine (dfmo) use in the human prostate | |
| AU2002362613A1 (en) | Galectins-1-and-4 in tumor development | |
| AU2001286721A1 (en) | Human interleukin-four induced protein | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU2002227925A1 (en) | Human beta-defensin-3 | |
| AU2001288921A1 (en) | Human breast cancer biomarkers | |
| AU8026300A (en) | Sodd gene expression in cancer | |
| AU2002215111A1 (en) | Ruthenium-aryl-compounds in cancer therapy | |
| AU2001236782A1 (en) | 34p3d7: a tissue specific protein highly expressed in prostate cancer | |
| AU6111800A (en) | 26 human prostate and prostate cancer associated proteins | |
| AU2001238144A1 (en) | 83p5g4: a tissue specific protein highly expressed in prostate cancer | |
| AU2001244863A1 (en) | Apoptin-associating protein | |
| AU2001289127A1 (en) | Tumor treatment | |
| AU2001268466A1 (en) | 55p4h4: gene expressed in various cancers |